Trial Profile
The Use of Rituximab in the Treatment of Idiopathic Membranous Nephropathy
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Membranous glomerulonephritis
- Focus Adverse reactions; Pharmacokinetics
- 24 Oct 2014 New trial record